Physician profile
Andrea E Ferrell
NPI 1396637153
$1,190.94
in general payments reported to CMS, 2019-2025
21 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $261.68 | 2025 | Talvey, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $113.84 | 2025 | Keytruda, Lynparza, Keytruda Qlex |
| Caris Mpi, INC. | $100.71 | 2025 | Mi Cancer Seek |
| Abbvie INC. | $86.96 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $68.96 | 2025 | Calquence |
| Novartis Pharmaceuticals Corporation | $68.15 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.23 | 2025 | Iclusig, Alunbrig |
| Genentech USA, INC. | $48.25 | 2025 | Polivy, Tecentriq |
| Genzyme Corporation | $46.63 | 2025 | |
| Incyte Corporation | $46.13 | 2025 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $40.57 | 2025 | Ojjaara, Blenrep, Jemperli |
| Tersera Therapeutics LLC | $37.36 | 2025 | Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $37.03 | 2025 | |
| Kite Pharma, INC. | $31.96 | 2025 | Yescarta |
| Eisai INC. | $29.43 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.24 | 2025 | Vyloy |
| Pharmaessentia USA Corporation | $20.83 | 2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $20.69 | 2025 | Monoferric |
| Azurity Pharmaceuticals, INC. | $18.51 | 2025 | Danziten |
| Karyopharm Therapeutics INC. | $16.60 | 2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $14.18 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.